期刊文献+

一种快速检测UGT1A1~*28基因多态性的方法 被引量:1

Detection of UGT1A1~*28 Polymorphism Using Fragment Analysis
下载PDF
导出
摘要 背景与目的尿苷二磷酸葡萄糖醛酸转移酶(uridine diphosphate glucuronosyl transferase 1A1,UGT1A1)是伊立替康代谢最主要的同工酶,UGT1A1基因的多态性影响UGT1A1的活性,本研究建立片段分析法检测UGT1A1*28 TATA盒的多态性。方法调取2014年4月-2015年5月在广东省人民医院的住院肺癌患者库存血液标本286例,建立片段分析法检测UGT1A1*28 TATA多态性,与Sanger测序方法比较其精确度和准确度。结果 286例肿瘤血液中,UGT1A1*28 TATA盒TA6/6型有236例(82.5%),TA6/7型有48例(16.8%),TA7/7型2例(0.7%)。片段分析法与Sanger测序法比较,精确度与准确度达100%。结论片段分析法适用于临床检测UGT1A1*28多态性,成本低且方便快捷。 Background and objective Uridine-diphosphoglucuronosyl transferase 1A1 (UGT1A1), UGT1A1*28 polymorphism can reduce UGT1A1 enzymatic activity, which may lead to severe toxicities in patients who receive irinotecan. This study tries to build a fragment analysis method to detect UGTIA1 *28 polymorphism. Methods A total of 286 blood specimens from the lung cancer patients who were hospitalized in Guangdong General Hospital between April 2014 to May 2015 were detected UGTIA1*28 polymorphism by fragment analysis method. Results Comparing with Sanger sequencing, precision and accuracy of the fragment analysis method were 100%. Of the 286 patients, 236 (82.5% harbored TA6/6 genotype, 48 (16.8%) TA 6/7 genotype and 2 (0.7%) TA7/7 genotype. Conclusion Our data suggest hat the fragment analysis method is robust for detecting UGT1A1 *28 polymorphism in clinical practice. It's simple, time-saving, and easy-to-carry.
出处 《中国肺癌杂志》 CAS CSCD 北大核心 2017年第12期817-821,共5页 Chinese Journal of Lung Cancer
基金 广东省科技厅重点实验室建设项目(No.2012A061400006)资助~~
关键词 UGT1A1 片段分析 基因多态性 UGT1A1 Fragment analysis Polymorphism
  • 相关文献

参考文献5

二级参考文献52

  • 1董强刚,黄进肃,黄建,卢丽琴,杨立民.肺癌靶向治疗研究进展与我国肺癌的EGFR基因突变概况[J].肿瘤,2005,25(6):625-628. 被引量:35
  • 2Garcia-Carbonero R,Supko JG.Current perspectives on the clinical experience,pharmacology,and continued development of the camptothecins.Clin Cancer Res 2002; 8:641-661.
  • 3Ulukan H,Swaan PW.Camptothecins:a review of their chemotherapeutic potential.Drugs 2002; 62:2039-2057.
  • 4Saltz LB,Cox JV,Blanke C,Rosen LS,Fehrenbacher L,Moore MJ,Maroun JA,Ackland SP,Locker PK,Pirotta N,Elfring GL,Miller LL.Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.Irinotecan Study Group.N Engl J Med 2000; 343:905-914.
  • 5Folprecht G,Kohne CH.The role of new agents in the treatment of colorectal cancer.Oncology 2004; 66:1-17.
  • 6Kawato Y,Aonuma M,Hirota Y,Kuga H,Sato K.Intracellular roles of SN-38,a metabolite of the camptothecin derivative CPT-11,in the antitumor effect of CPT-11.Cancer Res 1991; 51:4187-4191.
  • 7Vanhoefer U,Harstrick A,Achterrath W,Cao S,Seeber S,Rustum YM.Irinotecan in the treatment of colorectal cancer:clinical overview.J Clin Oncol 2001; 19:1501-1518.
  • 8Araki E,Ishikawa M,Iigo M,Koide T,Itabashi M,Hoshi A.Relationship between development of diarrhea and the concentration of SN-38,an active metabolite of CPT-11,in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11.Jpn J Cancer Res 1993; 84:697-702.
  • 9Gupta E,Lestingi TM,Mick R,Ramirez J,Vokes EE,Ratain MJ.Metabolic fate of irinotecan in humans:correlation of glucuronidation with diarrhea.Cancer Res 1994; 54:3723-3725.
  • 10Bosma PJ.Inherited disorders of bilirubin metabolism.J Hepatol 2003; 38:107-117.

共引文献85

同被引文献9

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部